5-bromo-N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine | 1201824-92-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine
• CAS: 1201824-92-1
• 化学式: C₁₈H₂₀BrN₃
• 分子量: 358.281
• InChiKey: ZKEBRBBXVUEFPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.17
• 重原子数：
  22.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.71
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  2-羟基吡啶 、 5-bromo-N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine 在 copper(l) iodide 、 仲丁胺 、 caesium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以31%的产率得到1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one
  参考文献：
  名称：

  Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)

  摘要：

  A variety of basic, heterocyclic templates has been reported as potassium-competitive, acid pump antagonists. Herein, we report a comparison of potencies of these templates and others to establish which offers the best start point for further systematic optimisation. Modifications were carried out to improve the developability profile of the more potent 1H-pyrrolo[2,3-c] pyridine template, affording molecules with improved overall in vitro characteristics versus the reported clinical candidate AR-H047108, and comparable to the clinically efficacious AZD-0865. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.002
• 作为产物：
  描述：

  5,7-二溴-2,3-二甲基-1H-吡咯并[2,3-c]吡啶 、 2,6-二甲基苄胺 在 potassium carbonate 作用下， 以80%的产率得到5-bromo-N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine
  参考文献：
  名称：

  Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)

  摘要：

  A variety of basic, heterocyclic templates has been reported as potassium-competitive, acid pump antagonists. Herein, we report a comparison of potencies of these templates and others to establish which offers the best start point for further systematic optimisation. Modifications were carried out to improve the developability profile of the more potent 1H-pyrrolo[2,3-c] pyridine template, affording molecules with improved overall in vitro characteristics versus the reported clinical candidate AR-H047108, and comparable to the clinically efficacious AZD-0865. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.002